Oncology Pilot To Highlight Disagreements Between US FDA And Sponsor For Advisory Committees
Executive Summary
'Point/Counterpoint' program grew out of Assessment Aid initiative in the Oncology Center of Excellence and will be unveiled at an upcoming ODAC meeting.
You may also be interested in...
US FDA’s Oncology Center In The Lockdown: ‘Business As Usual’
Amid the COVID-19 pandemic, Richard Pazdur doesn’t want the cancer patient forgotten. His solution: keep churning out approvals.
'The Pazdur Effect': A Tale Of Three US FDA Oncology Advisory Committee Meetings
ODAC meetings are usually few and far between – and rarely come with good news for the sponsor. Below are some lessons learned from the bounty (three!) held this week.
Keytruda Bladder Cancer Advisory Cmte. To Discuss Clinical Meaningfulness Of Complete Response Rate
US FDA's questions about Keytruda's increased response rate in Merck's study compared to the historical control were raised in a new point-counterpoint advisory committee briefing document format.